BCT-301

N/A

Report date: 2025/12/26 20:01:33

Base Information

Drug NameBCT-301

Drug Alias NameAnti-CD19 Chemically Induced Pluripotent Stem Cell (CiPSC)-Derived CAR-iT Cells therapy (The Third Affiliated Hospital Of Beijing University)BCT301BCT-301

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionAnti-CD19T lymphocyte replacements

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsAntiphospholipid SyndromeScleroderma, SystemicLupus Erythematosus, Systemic +[6]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesThe Third Affiliated Hospital Of Beijing University

China Registration ClassN/A

Develop Information

Active CompaniesThe Third Affiliated Hospital Of Beijing University

Inactive CompaniesN/A

Active IndicationsAntiphospholipid SyndromeScleroderma, SystemicLupus Erythematosus, Systemic +[6]

Inactive IndicationsN/A

Other Information

ATC CodeN/A